APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK1 Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NK1 Receptor Antagonist Market Outlook and Growth Opportunities 2026

23 December 2025193 pages

Choose your research edition.

Industry ResearchNK1 Receptor Antagonist Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal NK1 Receptor Antagonist Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal NK1 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK1 Receptor Antagonist Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal NK1 Receptor Antagonist Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global NK1 Receptor Antagonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NK1 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NK1 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NK1 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NK1 Receptor Antagonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NK1 Receptor Antagonist market include Glenmark, Heron Therapeutics, TerSera Therapeutics, Torrent Pharmaceuticals, Beijing Sihuan Pharmaceutical, Fresenius Kabi, Hansoh Pharma, Helsinn Healthcare and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global NK1 Receptor Antagonist market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NK1 Receptor Antagonist and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NK1 Receptor Antagonist revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global NK1 Receptor Antagonist market.

NK1 Receptor Antagonist Segment by Company

Glenmark

Heron Therapeutics

TerSera Therapeutics

Torrent Pharmaceuticals

Beijing Sihuan Pharmaceutical

Fresenius Kabi

Hansoh Pharma

Helsinn Healthcare

Jiangsu Hengrui Pharmaceuticals

Luoxin Pharmaceutical

Merck

Qilu Pharmaceutical

Yichang Humanwell Pharmaceutical

Chia Tai Tianqing Pharmaceutical

NK1 Receptor Antagonist Segment by Type

Netupitant

Maropitant

Rolapitant

Fosaprepitant

Aprepitant

Other

NK1 Receptor Antagonist Segment by Application

Hospital

Specialty Clinic

NK1 Receptor Antagonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global NK1 Receptor Antagonist status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the NK1 Receptor Antagonist key companies, revenue, market share, and recent developments.

3. To split the NK1 Receptor Antagonist breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions NK1 Receptor Antagonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NK1 Receptor Antagonist significant trends, drivers, influence factors in global and regions.

6. To analyze NK1 Receptor Antagonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK1 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1 Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NK1 Receptor Antagonist industry.

Chapter 3: Detailed analysis of NK1 Receptor Antagonist company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of NK1 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of NK1 Receptor Antagonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NK1 Receptor Antagonist Industry Trends Table 2. NK1 Receptor Antagonist Industry Drivers Table 3. NK1 Receptor Antagonist Industry Opportunities and Challenges Table 4. NK1 Receptor Antagonist Industry Restraints Table 5. Global NK1 Receptor Antagonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NK1 Receptor Antagonist Revenue Share by Company (2021-2026) Table 7. Global NK1 Receptor Antagonist Company Ranking, (2024-2026) & (US$ Million) Table 8. Global NK1 Receptor Antagonist Key Company Manufacturing Base & Headquarters Table 9. Global NK1 Receptor Antagonist Company, Product Type & Application Table 10. Global NK1 Receptor Antagonist Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global NK1 Receptor Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Netupitant Table 15. Significant Companies of Maropitant Table 16. Significant Companies of Rolapitant Table 17. Significant Companies of Fosaprepitant Table 18. Significant Companies of Aprepitant Table 19. Significant Companies of Other Table 20. Global NK1 Receptor Antagonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global NK1 Receptor Antagonist Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global NK1 Receptor Antagonist Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global NK1 Receptor Antagonist Sales Value Share by Type (2021-2026) Table 24. Global NK1 Receptor Antagonist Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Hospital Table 26. Significant Companies of Specialty Clinic Table 27. Global NK1 Receptor Antagonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global NK1 Receptor Antagonist Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global NK1 Receptor Antagonist Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global NK1 Receptor Antagonist Sales Value Share by Application (2021-2026) Table 31. Global NK1 Receptor Antagonist Sales Value Share by Application (2027-2032) Table 32. Global NK1 Receptor Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global NK1 Receptor Antagonist Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global NK1 Receptor Antagonist Sales Value Share by Region (2021-2026) Table 35. Global NK1 Receptor Antagonist Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global NK1 Receptor Antagonist Sales Value Share by Region (2027-2032) Table 37. Global NK1 Receptor Antagonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global NK1 Receptor Antagonist Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global NK1 Receptor Antagonist Sales Value Market Share by Country (2021-2026) Table 40. Global NK1 Receptor Antagonist Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global NK1 Receptor Antagonist Sales Value Market Share by Country (2027-2032) Table 42. Glenmark Company Information Table 43. Glenmark Business Overview Table 44. Glenmark NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Glenmark NK1 Receptor Antagonist Product Portfolio Table 46. Glenmark Recent Development Table 47. Heron Therapeutics Company Information Table 48. Heron Therapeutics Business Overview Table 49. Heron Therapeutics NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Heron Therapeutics NK1 Receptor Antagonist Product Portfolio Table 51. Heron Therapeutics Recent Development Table 52. TerSera Therapeutics Company Information Table 53. TerSera Therapeutics Business Overview Table 54. TerSera Therapeutics NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. TerSera Therapeutics NK1 Receptor Antagonist Product Portfolio Table 56. TerSera Therapeutics Recent Development Table 57. Torrent Pharmaceuticals Company Information Table 58. Torrent Pharmaceuticals Business Overview Table 59. Torrent Pharmaceuticals NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Torrent Pharmaceuticals NK1 Receptor Antagonist Product Portfolio Table 61. Torrent Pharmaceuticals Recent Development Table 62. Beijing Sihuan Pharmaceutical Company Information Table 63. Beijing Sihuan Pharmaceutical Business Overview Table 64. Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 66. Beijing Sihuan Pharmaceutical Recent Development Table 67. Fresenius Kabi Company Information Table 68. Fresenius Kabi Business Overview Table 69. Fresenius Kabi NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Fresenius Kabi NK1 Receptor Antagonist Product Portfolio Table 71. Fresenius Kabi Recent Development Table 72. Hansoh Pharma Company Information Table 73. Hansoh Pharma Business Overview Table 74. Hansoh Pharma NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Hansoh Pharma NK1 Receptor Antagonist Product Portfolio Table 76. Hansoh Pharma Recent Development Table 77. Helsinn Healthcare Company Information Table 78. Helsinn Healthcare Business Overview Table 79. Helsinn Healthcare NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Helsinn Healthcare NK1 Receptor Antagonist Product Portfolio Table 81. Helsinn Healthcare Recent Development Table 82. Jiangsu Hengrui Pharmaceuticals Company Information Table 83. Jiangsu Hengrui Pharmaceuticals Business Overview Table 84. Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Product Portfolio Table 86. Jiangsu Hengrui Pharmaceuticals Recent Development Table 87. Luoxin Pharmaceutical Company Information Table 88. Luoxin Pharmaceutical Business Overview Table 89. Luoxin Pharmaceutical NK1 Receptor Antagonist Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Luoxin Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 91. Luoxin Pharmaceutical Recent Development Table 92. Merck Company Information Table 93. Merck Business Overview Table 94. Merck NK1 Receptor Antagonist Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Merck NK1 Receptor Antagonist Product Portfolio Table 96. Merck Recent Development Table 97. Qilu Pharmaceutical Company Information Table 98. Qilu Pharmaceutical Business Overview Table 99. Qilu Pharmaceutical NK1 Receptor Antagonist Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Qilu Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 101. Qilu Pharmaceutical Recent Development Table 102. Yichang Humanwell Pharmaceutical Company Information Table 103. Yichang Humanwell Pharmaceutical Business Overview Table 104. Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 106. Yichang Humanwell Pharmaceutical Recent Development Table 107. Chia Tai Tianqing Pharmaceutical Company Information Table 108. Chia Tai Tianqing Pharmaceutical Business Overview Table 109. Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 111. Chia Tai Tianqing Pharmaceutical Recent Development Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. NK1 Receptor Antagonist Product Image Figure 2. Global NK1 Receptor Antagonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK1 Receptor Antagonist Market Size (2021-2032) & (US$ Million) Figure 4. Global NK1 Receptor Antagonist Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Netupitant Image Figure 8. Maropitant Image Figure 9. Rolapitant Image Figure 10. Fosaprepitant Image Figure 11. Aprepitant Image Figure 12. Other Image Figure 13. Global NK1 Receptor Antagonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global NK1 Receptor Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global NK1 Receptor Antagonist Sales Value Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Specialty Clinic Image Figure 18. Global NK1 Receptor Antagonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global NK1 Receptor Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global NK1 Receptor Antagonist Sales Value Share by Application (2021-2032) Figure 21. Global NK1 Receptor Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global NK1 Receptor Antagonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America NK1 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 24. North America NK1 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe NK1 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 26. Europe NK1 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific NK1 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific NK1 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America NK1 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 30. South America NK1 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa NK1 Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa NK1 Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Netupitant
  • Maropitant
  • Rolapitant
  • Fosaprepitant
  • Aprepitant
  • Other
Applications
  • Hospital
  • Specialty Clinic
Companies covered
  • Glenmark
  • Heron Therapeutics
  • TerSera Therapeutics
  • Torrent Pharmaceuticals
  • Beijing Sihuan Pharmaceutical
  • Fresenius Kabi
  • Hansoh Pharma
  • Helsinn Healthcare
  • Jiangsu Hengrui Pharmaceuticals
  • Luoxin Pharmaceutical
  • Merck
  • Qilu Pharmaceutical
  • Yichang Humanwell Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NK1 Receptor Antagonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NK1 Receptor Antagonist Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 NK1 Receptor Antagonist Market Dynamics
  1. 2.1 NK1 Receptor Antagonist Industry Trends
  2. 2.2 NK1 Receptor Antagonist Industry Drivers
  3. 2.3 NK1 Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 NK1 Receptor Antagonist Industry Restraints
3 NK1 Receptor Antagonist Market by Company
  1. 3.1 Global NK1 Receptor Antagonist Company Revenue Ranking in 2025
  2. 3.2 Global NK1 Receptor Antagonist Revenue by Company (2021-2026)
  3. 3.3 Global NK1 Receptor Antagonist Company Ranking (2024-2026)
  4. 3.4 Global NK1 Receptor Antagonist Company Manufacturing Base and Headquarters
  5. 3.5 Global NK1 Receptor Antagonist Company Product Type and Application
  6. 3.6 Global NK1 Receptor Antagonist Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global NK1 Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 NK1 Receptor Antagonist Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 NK1 Receptor Antagonist Market by Type
  1. 4.1 NK1 Receptor Antagonist Type Introduction
  2. 4.1.1 Netupitant
  3. 4.1.2 Maropitant
  4. 4.1.3 Rolapitant
  5. 4.1.4 Fosaprepitant
  6. 4.1.5 Aprepitant
  7. 4.1.6 Other
  8. 4.2 Global NK1 Receptor Antagonist Sales Value by Type
  9. 4.2.1 Global NK1 Receptor Antagonist Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global NK1 Receptor Antagonist Sales Value by Type (2021-2032)
  11. 4.2.3 Global NK1 Receptor Antagonist Sales Value Share by Type (2021-2032)
5 NK1 Receptor Antagonist Market by Application
  1. 5.1 NK1 Receptor Antagonist Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Specialty Clinic
  4. 5.2 Global NK1 Receptor Antagonist Sales Value by Application
  5. 5.2.1 Global NK1 Receptor Antagonist Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global NK1 Receptor Antagonist Sales Value by Application (2021-2032)
  7. 5.2.3 Global NK1 Receptor Antagonist Sales Value Share by Application (2021-2032)
6 NK1 Receptor Antagonist Regional Value Analysis
  1. 6.1 Global NK1 Receptor Antagonist Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NK1 Receptor Antagonist Sales Value by Region (2021-2032)
  3. 6.2.1 Global NK1 Receptor Antagonist Sales Value by Region: 2021-2026
  4. 6.2.2 Global NK1 Receptor Antagonist Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NK1 Receptor Antagonist Sales Value (2021-2032)
  7. 6.3.2 North America NK1 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe NK1 Receptor Antagonist Sales Value (2021-2032)
  10. 6.4.2 Europe NK1 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific NK1 Receptor Antagonist Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific NK1 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America NK1 Receptor Antagonist Sales Value (2021-2032)
  16. 6.6.2 South America NK1 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa NK1 Receptor Antagonist Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa NK1 Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
7 NK1 Receptor Antagonist Country-level Value Analysis
  1. 7.1 Global NK1 Receptor Antagonist Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NK1 Receptor Antagonist Sales Value by Country (2021-2032)
  3. 7.2.1 Global NK1 Receptor Antagonist Sales Value by Country (2021-2026)
  4. 7.2.2 Global NK1 Receptor Antagonist Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt NK1 Receptor Antagonist Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt NK1 Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt NK1 Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Glenmark
  2. 8.1.1 Glenmark Company Information
  3. 8.1.2 Glenmark Business Overview
  4. 8.1.3 Glenmark NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Glenmark NK1 Receptor Antagonist Product Portfolio
  6. 8.1.5 Glenmark Recent Developments
  7. 8.2 Heron Therapeutics
  8. 8.2.1 Heron Therapeutics Company Information
  9. 8.2.2 Heron Therapeutics Business Overview
  10. 8.2.3 Heron Therapeutics NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Heron Therapeutics NK1 Receptor Antagonist Product Portfolio
  12. 8.2.5 Heron Therapeutics Recent Developments
  13. 8.3 TerSera Therapeutics
  14. 8.3.1 TerSera Therapeutics Company Information
  15. 8.3.2 TerSera Therapeutics Business Overview
  16. 8.3.3 TerSera Therapeutics NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  17. 8.3.4 TerSera Therapeutics NK1 Receptor Antagonist Product Portfolio
  18. 8.3.5 TerSera Therapeutics Recent Developments
  19. 8.4 Torrent Pharmaceuticals
  20. 8.4.1 Torrent Pharmaceuticals Company Information
  21. 8.4.2 Torrent Pharmaceuticals Business Overview
  22. 8.4.3 Torrent Pharmaceuticals NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Torrent Pharmaceuticals NK1 Receptor Antagonist Product Portfolio
  24. 8.4.5 Torrent Pharmaceuticals Recent Developments
  25. 8.5 Beijing Sihuan Pharmaceutical
  26. 8.5.1 Beijing Sihuan Pharmaceutical Company Information
  27. 8.5.2 Beijing Sihuan Pharmaceutical Business Overview
  28. 8.5.3 Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  30. 8.5.5 Beijing Sihuan Pharmaceutical Recent Developments
  31. 8.6 Fresenius Kabi
  32. 8.6.1 Fresenius Kabi Company Information
  33. 8.6.2 Fresenius Kabi Business Overview
  34. 8.6.3 Fresenius Kabi NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fresenius Kabi NK1 Receptor Antagonist Product Portfolio
  36. 8.6.5 Fresenius Kabi Recent Developments
  37. 8.7 Hansoh Pharma
  38. 8.7.1 Hansoh Pharma Company Information
  39. 8.7.2 Hansoh Pharma Business Overview
  40. 8.7.3 Hansoh Pharma NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hansoh Pharma NK1 Receptor Antagonist Product Portfolio
  42. 8.7.5 Hansoh Pharma Recent Developments
  43. 8.8 Helsinn Healthcare
  44. 8.8.1 Helsinn Healthcare Company Information
  45. 8.8.2 Helsinn Healthcare Business Overview
  46. 8.8.3 Helsinn Healthcare NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Helsinn Healthcare NK1 Receptor Antagonist Product Portfolio
  48. 8.8.5 Helsinn Healthcare Recent Developments
  49. 8.9 Jiangsu Hengrui Pharmaceuticals
  50. 8.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 8.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 8.9.3 Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Product Portfolio
  54. 8.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 8.10 Luoxin Pharmaceutical
  56. 8.10.1 Luoxin Pharmaceutical Company Information
  57. 8.10.2 Luoxin Pharmaceutical Business Overview
  58. 8.10.3 Luoxin Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Luoxin Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  60. 8.10.5 Luoxin Pharmaceutical Recent Developments
  61. 8.11 Merck
  62. 8.11.1 Merck Company Information
  63. 8.11.2 Merck Business Overview
  64. 8.11.3 Merck NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Merck NK1 Receptor Antagonist Product Portfolio
  66. 8.11.5 Merck Recent Developments
  67. 8.12 Qilu Pharmaceutical
  68. 8.12.1 Qilu Pharmaceutical Company Information
  69. 8.12.2 Qilu Pharmaceutical Business Overview
  70. 8.12.3 Qilu Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Qilu Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  72. 8.12.5 Qilu Pharmaceutical Recent Developments
  73. 8.13 Yichang Humanwell Pharmaceutical
  74. 8.13.1 Yichang Humanwell Pharmaceutical Company Information
  75. 8.13.2 Yichang Humanwell Pharmaceutical Business Overview
  76. 8.13.3 Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  78. 8.13.5 Yichang Humanwell Pharmaceutical Recent Developments
  79. 8.14 Chia Tai Tianqing Pharmaceutical
  80. 8.14.1 Chia Tai Tianqing Pharmaceutical Company Information
  81. 8.14.2 Chia Tai Tianqing Pharmaceutical Business Overview
  82. 8.14.3 Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  84. 8.14.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst